Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


03.06.2019

1 Ann Oncol
1 Ann Surg Oncol
2 Arch Bronconeumol
2 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
1 Cancer Res
2 Chest
1 Clin Lung Cancer
2 Eur J Cancer
2 Int J Cancer
1 Int J Oncol
1 J Cancer Res Clin Oncol
3 J Thorac Cardiovasc Surg
6 J Thorac Oncol
1 Lancet
2 Lancet Oncol
1 Oncogene
2 Oncologist
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. MAZIERES J, Drilon A, Lusque A, Mhanna L, et al
    Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
    Ann Oncol. 2019 May 24. pii: 5498206. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. PASTORINO U, Morelli D, Leuzzi G, Rolli L, et al
    Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy.
    Ann Surg Oncol. 2019;26:869-875.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  3. FENG C, Zhao Y, Li Y, Zhang T, et al
    LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge.
    Arch Bronconeumol. 2019 May 24. pii: S0300-2896(19)30227.
    PubMed     Text format     Abstract available

  4. YAMASAKI M, Funaishi K, Daido W, Hattori N, et al
    Acquired T790M-positive Squamous Cell Lung Carcinoma that Responded to Osimertinib.
    Arch Bronconeumol. 2019 May 20. pii: S0300-2896(19)30220.
    PubMed     Text format    


    BMC Cancer

  5. BHAT GR, Bhat A, Verma S, Sethi I, et al
    Association of newly identified genetic variant rs2853677 of TERT with non-small cell lung cancer and leukemia in population of Jammu and Kashmir, India.
    BMC Cancer. 2019;19:493.
    PubMed     Text format     Abstract available

  6. WANG J, Chen J
    Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    BMC Cancer. 2019;19:131.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  7. LIN S, Nickens DJ, Patel M, Wilner KD, et al
    Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 May 24. pii: 10.1007/s00280-019-03861.
    PubMed     Text format     Abstract available


    Cancer Lett

  8. LIU X, Pu W, He H, Fan X, et al
    Novel ROR1 Inhibitor ARI-1 Suppresses the Development of Non-Small Cell Lung Cancer.
    Cancer Lett. 2019 May 21. pii: S0304-3835(19)30311.
    PubMed     Text format     Abstract available


    Cancer Res

  9. SASAKI Y, Fujimori H, Hozumi M, Onodera T, et al
    Dysfunction of poly(ADP-ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells.
    Cancer Res. 2019 May 29. pii: 0008-5472.CAN-18-1037.
    PubMed     Text format     Abstract available


    Chest

  10. TZOUVELEKIS A, Gomatou G, Bouros E, Trigidou R, et al
    Common Pathogenetic Mechanisms Between IPF and Lung Cancer.
    Chest. 2019 May 21. pii: S0012-3692(19)31095-5. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available

  11. YANG M, Shen Y, Tan L, Li W, et al
    Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis.
    Chest. 2019 May 22. pii: S0012-3692(19)31097-9. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  12. SCHWARTZBERG L, Korytowsky B, Penrod JR, Zhang Y, et al
    Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
    Clin Lung Cancer. 2019 Apr 19. pii: S1525-7304(19)30084.
    PubMed     Text format     Abstract available


    Eur J Cancer

  13. SCHOENMAEKERS J, Hofman P, Bootsma G, Westenend M, et al
    Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
    Eur J Cancer. 2019;115:88-96.
    PubMed     Text format     Abstract available

  14. FOUCHARD M, Jantzem H, Quere G, Descourt R, et al
    Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Eur J Cancer. 2019;115:107-110.
    PubMed     Text format    


    Int J Cancer

  15. ZHANG C, Ding H, Huang H, Palashati H, et al
    TCR repertoire intratumor heterogeneity of CD4(+) and CD8(+) T cells in centers and margins of localized lung adenocarcinomas.
    Int J Cancer. 2019;144:818-827.
    PubMed     Text format     Abstract available

  16. SONG H, Sun B, Liao Y, Xu D, et al
    GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
    Int J Cancer. 2019;144:777-787.
    PubMed     Text format     Abstract available


    Int J Oncol

  17. LIU L, Liu L, Lu S
    lncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3.
    Int J Oncol. 2019;54:929-941.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  18. PARK JH, Kwon BS, Park SJ, Ji W, et al
    Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2019 May 29. pii: 10.1007/s00432-019-02941.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  19. HENDRIKSEN BS, Hollenbeak CS, Reed MF, Taylor MD, et al
    Perioperative chemotherapy is not associated with improved survival in stage I pleomorphic lung cancer.
    J Thorac Cardiovasc Surg. 2019 Apr 17. pii: S0022-5223(19)30824.
    PubMed     Text format     Abstract available

  20. OSAROGIAGBON RU, Lee YS, Faris NR, Ray MA, et al
    Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort.
    J Thorac Cardiovasc Surg. 2019 May 2. pii: S0022-5223(19)30968.
    PubMed     Text format     Abstract available

  21. SUBRAMANIAN M, Liu J, Greenberg C, Schumacher J, et al
    Imaging Surveillance for Surgically Resected Stage I Non-Small Cell Lung Cancer: Is More Always Better?
    J Thorac Cardiovasc Surg. 2019;157:1205-1217.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  22. MILLER AB
    Improving Surveillance following Treatment for Lung Cancer.
    J Thorac Oncol. 2019;14:955.
    PubMed     Text format    

  23. ADJEI AA
    Lung Cancer Worldwide.
    J Thorac Oncol. 2019;14:956.
    PubMed     Text format    

  24. JAZIEH AR, Algwaiz G, Alshehri SM, Alkattan K, et al
    Lung Cancer in Saudi Arabia.
    J Thorac Oncol. 2019;14:957-962.
    PubMed     Text format    

  25. GONG L, Qin J, Xie F, Han N, et al
    The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient With Afatinib-Resistant Lung Cancer.
    J Thorac Oncol. 2019;14:e120-e123.
    PubMed     Text format    

  26. GOMEZ DR, Rimner A, Simone CB 2nd, Cho BCJ, et al
    The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applie
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30380.
    PubMed     Text format     Abstract available

  27. PARK S, Lee H, Lee B, Lee SH, et al
    DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30381.
    PubMed     Text format     Abstract available


    Lancet

  28. LOO BW JR, Diehn M
    SABR-COMET: harbinger of a new cancer treatment paradigm.
    Lancet. 2019;393:2013-2014.
    PubMed     Text format    


    Lancet Oncol

  29. WEST H, McCleod M, Hussein M, Morabito A, et al
    Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30167.
    PubMed     Text format     Abstract available

  30. LI Y, Wu YL
    The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer.
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30148.
    PubMed     Text format    


    Oncogene

  31. LU CH, Yeh DW, Lai CY, Liu YL, et al
    Correction: USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation.
    Oncogene. 2019 May 30. pii: 10.1038/s41388-019-0831.
    PubMed     Text format     Abstract available


    Oncologist

  32. MELOSKY B, Juergens R, Hirsh V, McLeod D, et al
    Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
    Oncologist. 2019 May 28. pii: theoncologist.2019-0027.
    PubMed     Text format     Abstract available

  33. LEE JH, Chen HY, Hsu FM, Chen JS, et al
    Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
    Oncologist. 2019 May 24. pii: theoncologist.2019-0152.
    PubMed     Text format     Abstract available


    PLoS One

  34. THEELEN WSME, Kuilman T, Schulze K, Zou W, et al
    Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNgamma signaling in non-small cell lung cancer.
    PLoS One. 2019;14:e0216864.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: